These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30244106)

  • 1. Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplantation.
    Mikhael J
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):e1-e2. PubMed ID: 30244106
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease?
    Bridoux F; Javaugue V; Fermand JP; Jaccard A
    Nephrol Dial Transplant; 2016 Aug; 31(8):1199-202. PubMed ID: 26908764
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
    Hong S; Valent J; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill B; Kalaycio ME; Pohlman B; Reu F; Samaras C; Sobecks R; Majhail NS; Liu HD
    Bone Marrow Transplant; 2016 May; 51(5):732-4. PubMed ID: 26726941
    [No Abstract]   [Full Text] [Related]  

  • 4. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous Stem Cell Transplantation in Light Chain Amyloidosis: The Ultimate Treatment?
    Varga C
    Transplant Cell Ther; 2022 Feb; 28(2):57-58. PubMed ID: 35115132
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
    Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
    Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atraumatic Splenic Rupture Due to Ectopic Extramedullary Hematopoiesis after Autologous Stem Cell Transplantation in a Patient with AL Amyloidosis.
    Sato S; Tamai Y; Okada S; Kannbe E; Takeda K; Tanaka E
    Intern Med; 2018 Feb; 57(3):399-402. PubMed ID: 29093392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
    Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome.
    Biliński J; Biernacka EK; Januszewicz A
    Eur Heart J; 2021 Sep; 42(36):3803. PubMed ID: 34165537
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Stem Cell Transplantation in Patients With Primary Systemic Amyloidosis: Experience of a Tertiary Hospital.
    Domínguez-Muñoz MA; Calderón-Cabrera C; Martino-Galiana ML; Martín-Sánchez J
    Transplant Proc; 2015 Nov; 47(9):2661-4. PubMed ID: 26680066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].
    Adam Z; Ozábalová E; Němec P; Bedáňová H; Kuman M; Krejčí J; Špinarová L; Žampachová V; Čermáková Z; Pour L; Krejčí M; Sanecká V; Štork M; Pika T; Straub J; Adamová D; Stavařová Y; Král Z; Mayer J
    Vnitr Lek; 2018; 64(4):441-449. PubMed ID: 29791180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
    Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
    Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
    Sanchorawala V
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience.
    Azorín SE; Cibeira MT; Solé M; Fernández de Larrea C; Rosiñol L; Rovira M; Campistol JM; Bladé J
    Amyloid; 2017 Mar; 24(sup1):70-71. PubMed ID: 28434321
    [No Abstract]   [Full Text] [Related]  

  • 20. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
    Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
    Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.